Pepgen Corporation

Yoshihiro Sokawa

Chih-Ping Liu

A method for treating a condition responsive to interferon therapy in a human subject is described. The method includes orally administering interferon-tau to the intestinal tract in an amount effective to produce an increase in the subject's blood 2', 5&#x2032;-oligoadenylate synthetase (OAS) level, relative to the OAS level in the subject in the absence of interferon-tau.

Method of treatment using interferon-tau

A method of monitoring treatment of HCV by oral administration of ovine IFN-&#x3c4; is disclosed. The method includes measuring the blood levels of 2',5&#x2032;-oligoadenylate synthetase prior to and after such oral administration, and if necessary, adjusting the dose of IFN-&#x3c4; until a measurable increase in blood 2&#x2032;,5&#x2032;-oligoadenylate synthetase level, relative to the level observed prior to administration, is observed. Also disclosed are oral-delivery compositions for use in treating HCV in an HCV-infected patient comprising ovine IFN-&#x3c4;, in a dosage effective to stimulate bloodstream levels of 2&#x2032;,5&#x2032;-oligoadenylate synthetase.

Growing community of inventors

Kyoto, Japan

Yoshihiro Sokawa